Canada's Blood Services Spends $1-billion Annually on Plasma-Derived Drugs.

Canadian Blood Services spent nearly $1 billion last year on pharmaceutical products derived from human plasma, accounting for 64% of its budget. The demand for these products has rapidly grown, leading to an expansion of Spanish pharmaceutical company Grifols' Canadian footprint. The majority of collected plasma is used for drug manufacturing, with only a small portion used for transfusions. The growth in demand has raised concerns, including the deaths of two people after visiting Grifols' collection centers in Winnipeg.